Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
72.16
+0.38 (0.53%)
Nov 2, 2026, 4:00 PM EST - Market closed
Inhibrx Biosciences Market Cap
Inhibrx Biosciences has a market cap or net worth of $1.06 billion as of November 2, 2026. It is the 9,632nd most valuable company in the world and the 2,195th biggest in the United States. Its market cap has decreased by 10.22% in one year.
Market Cap
1.06B
Enterprise Value
1.11B
1-Year Change
-10.22%
Global Rank
Country Rank
#2,195 United States
Category
ChartMarket Cap Chart
Since May 29, 2024, Inhibrx Biosciences's market cap has increased from $198.24M to $1.06B, an increase of 435.74%. That is a compound annual growth rate of 99.51%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 2, 2026 | 1.06B | -7.57% |
| Dec 31, 2025 | 1.15B | 415.39% |
| Dec 31, 2024 | 222.93M | 12.46% |
| May 29, 2024 | 198.24M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Avalyn Pharma | 1.14B |
| MannKind | 1.13B |
| SpyGlass Pharma | 1.08B |
| Janux Therapeutics | 1.07B |
| Seaport Therapeutics | 1.05B |
| City Therapeutics | 1.03B |
| MoonLake Immunotherapeutics | 1.00B |
| Immatics | 984.17M |